OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering & Therapeutics Conference
OmniAb (NASDAQ: OABI) presented two key technologies at the 2024 Antibody Engineering & Therapeutics Conference in San Diego. The first presentation showcased the company's workflow for building multispecifics, including CD3 T cell and NK cell engagers, highlighting their naturally optimized human sequence immune repertoires and AI-augmented single B cell workflows. The second presentation introduced OmniHub™, a high-dimensional unified bioinformatics portal designed to enhance partner experience through scalable data transfer, advanced visualization, and comprehensive tool access.
The company demonstrated how they discovered developable anti-NKp46 binders with broad epitope coverage, utilizing high-throughput phenotypic screening enhanced with AI-guided next-generation sequencing workflow to identify high-quality leads without extensive ex vivo engineering.
OmniAb (NASDAQ: OABI) ha presentato due tecnologie chiave alla Conferenza 2024 sull'Ingegneria e Terapie degli Anticorpi a San Diego. La prima presentazione ha mostrato il flusso di lavoro dell'azienda per la creazione di multispecifici, inclusi gli ingaggiatori delle cellule T CD3 e delle cellule NK, evidenziando i loro repertori immunitari umani ottimizzati e i flussi di lavoro per cellule B singole potenziati dall'AI. La seconda presentazione ha introdotto OmniHub™, un portale bioinformatico unificato ad alta dimensione progettato per migliorare l'esperienza dei partner attraverso il trasferimento scalabile dei dati, la visualizzazione avanzata e l'accesso a strumenti completi.
L'azienda ha dimostrato come ha scoperto leganti anti-NKp46 sviluppabili con una copertura epitope ampia, utilizzando screening fenotipici ad alta capacità migliorati da un flusso di lavoro di sequenziamento di nuova generazione guidato dall'AI per identificare lead di alta qualità senza la necessità di un'ampia ingegneria ex vivo.
OmniAb (NASDAQ: OABI) presentó dos tecnologías clave en la Conferencia de Ingeniería y Terapias de Anticuerpos 2024 en San Diego. La primera presentación mostró el flujo de trabajo de la empresa para construir multispecíficos, incluidos los activadores de células T CD3 y células NK, destacando sus repertorios inmunitarios humanos optimizados de forma natural y flujos de trabajo de células B individuales potenciados por IA. La segunda presentación introdujo OmniHub™, un portal de bioinformática unificado y de alta dimensión diseñado para mejorar la experiencia de los socios a través de la transferencia de datos escalable, visualización avanzada y acceso completo a herramientas.
La empresa demostró cómo descubrió ligandos anti-NKp46 desarrollables con amplia cobertura de epítopos, utilizando un cribado fenotípico de alto rendimiento mejorado con un flujo de trabajo de secuenciación de próxima generación guiado por IA para identificar leads de alta calidad sin una ingeniería ex vivo extensa.
OmniAb (NASDAQ: OABI)는 샌디에이고에서 열린 2024 항체 공학 및 치료 회의에서 두 가지 주요 기술을 발표했습니다. 첫 번째 발표에서는 CD3 T 세포 및 NK 세포 유도제를 포함한 다특이성 제품을 구축하기 위한 회사의 작업 흐름을 보여주었으며, 자연적으로 최적화된 인간 면역 레퍼토리와 AI 보강 단일 B 세포 작업 흐름을 강조했습니다. 두 번째 발표에서는 OmniHub™를 소개했으며, 이는 확장 가능한 데이터 전송, 고급 시각화 및 종합적인 도구 접근을 통해 파트너 경험을 향상시키기 위해 설계된 고차원 통합 생물정보학 포털입니다.
회사는 광범위한 에피토프 범위를 가진 개발 가능한 항 NKp46 결합제를 발견하는 방법을 시연했으며, AI 지침 차세대 시퀀싱 작업 흐름을 강화한 고처리량 유전자 표현형 스크리닝을 활용하여 폭넓은 고품질 리드를 식별했습니다.
OmniAb (NASDAQ: OABI) a présenté deux technologies clés lors de la Conférence 2024 sur l'Ingénierie et les Thérapies des Anticorps à San Diego. La première présentation a mis en avant le flux de travail de l'entreprise pour la construction de multispecifiques, y compris des engageurs de cellules T CD3 et de cellules NK, soulignant leurs répertoires immunitaires humains naturellement optimisés et les flux de travail de cellules B uniques augmentés par l'IA. La seconde présentation a introduit OmniHub™, un portail bioinformatique unifié en haute dimension conçu pour améliorer l'expérience des partenaires grâce à un transfert de données évolutif, une visualisation avancée et un accès complet aux outils.
L'entreprise a démontré comment elle a découvert des liaisons anti-NKp46 développables avec une large couverture d'épitopes, en utilisant un criblage phénotypique à haut débit amélioré par un flux de travail de séquençage de nouvelle génération guidé par l'IA pour identifier des pistes de haute qualité sans avoir besoin d'une ingénierie ex vivo étendue.
OmniAb (NASDAQ: OABI) stellte auf der Antibody Engineering & Therapeutics Conference 2024 in San Diego zwei Schlüsseltechnologien vor. Die erste Präsentation zeigte den Arbeitsablauf des Unternehmens zur Erstellung von Multispezifischen, einschließlich CD3 T-Zell- und NK-Zell-Aktivatoren, und hob deren natürlich optimierte menschliche Immunrepertoire sowie KI-unterstützte Einzel-B-Zell-Arbeitsabläufe hervor. Die zweite Präsentation stellte OmniHub™ vor, ein hochdimensionales, einheitliches Bioinformatik-Portal, das darauf ausgelegt ist, die Partnererfahrung durch skalierbaren Datentransfer, erweiterte Visualisierung und umfassenden Zugang zu Werkzeugen zu verbessern.
Das Unternehmen demonstrierte, wie es entwickelbare Anti-NKp46-Binder mit breiter Epitop-Abdeckung entdeckte und dazu AI-gesteuerte Next-Generation-Sequencing-Arbeitsabläufe in der Hochdurchsatz-Phänotypisierung nutzte, um hochwertige Leads ohne umfangreiche ex vivo-Engineering zu identifizieren.
- Implementation of AI-augmented workflows for antibody discovery
- Launch of OmniHub™ bioinformatics platform enhancing partner capabilities
- Demonstrated success in developing clinical-stage and approved bispecifics
- None.
Presentations included a case study of the workflow for building multispecifics and the launch of OmniHub™, a bioinformatics tools platform
In a presentation titled “Building Multispecifics from in vivo Derived Antibody Domains and Alternative Scaffolds,” Yasmina Abdiche, Ph.D., Vice President of Exploratory Research, provided an overview of building multispecifics ranging from traditional CD3 T cell engagers to next-generation NK cell engagers, facilitated by emerging targets such as NKp46.
“OmniAb’s technologies offer significant advantages in multispecifics, including naturally optimized human sequence immune repertoires across multiple host species, a variety of antibody modalities to support novel molecular formats, and artificial intelligence (AI)-augmented single B cell workflows for deep repertoire mining,” said Matt Foehr, Chief Executive Officer of OmniAb. “We have a strong track record of delivering candidates which lead to clinical-stage and approved bispecifics, where on-target specificity, developability, tunable affinity and broad epitope coverage are all important elements. Leveraging this foundation, our platform offers versatile multi-modality options, providing our partners with the flexibility to execute their campaigns effectively.”
“This case study presentation demonstrates how we discovered developable anti-NKp46 binders with broad epitope coverage and affinities, serving as building blocks for NK cell engager multispecifics. We enhanced high-throughput phenotypic screening with AI-guided next-generation sequencing workflow to explore the vast sequence space and identify high-quality leads, thereby avoiding extensive ex vivo engineering,” added Dr. Abdiche.
At AETC the Company also highlighted OmniHub™, a high-dimensional unified bioinformatics portal, in a presentation titled “Design and Implementation of OmniHub™, A Platform for Bioinformatics Tools Facilitating Antibody Discovery Workflows,” by Swetha Garimalla, Ph.D., Director of Computational Immunology. OmniHub™ is part of OmniAb’s ongoing commitment to enhancing the partner experience with its technologies and services. OmniHub™ enables scalable and secure data transfer, advanced visualization and comprehensive tool access.
OmniAb is showcasing its entire technology stack at the 2024 Antibody Engineering & Therapeutics Conference December 15-18 at exhibit booth #300 at the Marriott Marquis San Diego Marina.
About OmniAb®
OmniAb licenses cutting edge discovery research technology to the pharmaceutical and biotech industries and academic institutions to enable the discovery of next-generation therapeutics. Our technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for our partners’ drug development efforts. At the heart of the OmniAb platform is what we call Biological Intelligence™ (BI), which powers the immune systems of our proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.
We believe the OmniAb animals comprise the most diverse host systems available in the industry. Our suite of technologies and methods, including computational antigen design and immunization methods, paired with high-throughput single B cell phenotypic screening and mining of next-generation sequencing datasets with custom algorithms, are used to identify fully-human antibodies with exceptional performance and developability characteristics.
Our proprietary transgenic animals, including OmniRat®, OmniChicken® and OmniMouse® have been genetically modified to generate antibodies with human sequences to streamline the development of human therapeutic candidates. OmniFlic® and OmniClic® are fixed or common light-chain rats and chickens, respectively, designed to facilitate the discovery of bispecific antibodies. OmniTaur™ provides cow-inspired antibodies with unique structural characteristics for challenging targets. OmnidAb™ is an in vivo platform for the discovery of single-domain antibodies based upon a human VH scaffold that affinity matures in a chicken host environment to provide a functionally diverse immune repertoire unavailable from mammalian systems. Our proprietary technologies are joined with and leverage OmniDeep™, which is a suite of in silico, AI and machine learning tools for therapeutic discovery and optimization that are woven throughout our various technologies and capabilities. Additionally, an established core competency focused on ion channels and transporters further differentiates OmniAb’s technology and creates opportunities in many important and emerging target classes.
OmniAb technologies can be leveraged for the discovery of a variety of next-generation antibody-based therapeutic modalities, including bi- and multi-specific biologics, antibody-drug conjugates, CAR-T therapies, targeted radiotherapeutics and many others.
For more information, please visit www.omniab.com.
Forward-Looking Statements
OmniAb cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. Words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or continue” and similar expressions, are intended to identify forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to: the expected performance of our technologies and their impact on our partners; and the ability of our technologies to generate antibodies which will progress into the clinic or received marketing approval. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: our future success is dependent on acceptance of our technology platform and technologies by new and existing partners, as well as on the eventual development, approval and commercialization of products developed by our partners for which we have no control over the development plan, regulatory strategy or commercialization efforts; biopharmaceutical development is inherently uncertain; risks arising from changes in technology; and other risks described in our prior press releases and filings with the SEC, including under the heading “Risk Factors” in our annual report on Form 10-K and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241216917013/en/
OmniAb, Inc.
Neha Singh, Ph. D.
investors@OmniAb.com
X @OmniAbTech
(510) 768-7760
Source: OmniAb, Inc.
FAQ
What technologies did OmniAb (OABI) present at the 2024 Antibody Engineering Conference?
What is OmniHub™ and how does it benefit OABI partners?
How does OmniAb (OABI) utilize AI in their antibody discovery process?
What advantages does OmniAb's (OABI) multispecifics technology offer?
